300 Participants Needed

Enhanced Liver Function Test for Fatty Liver

KV
BB
Overseen ByBethany Brauer, MPH
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Methodist Health System
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial examines the Enhanced Liver Function (ELF) test to determine its effectiveness in detecting early signs of liver problems, such as fatty liver disease, in individuals with certain health conditions. These conditions may include high cholesterol, heart disease, high blood pressure, or type 2 diabetes. The goal is to assess whether this test can predict liver problems more accurately than other methods, such as scans or blood tests. Individuals who have already undergone an ELF test and have specific health conditions might be suitable candidates for this study. As an unphased trial, this study provides a unique opportunity to contribute to research that could enhance early detection of liver issues.

Why are researchers excited about this trial?

Researchers are excited about the Enhanced Liver Function (ELF) test because it offers a promising new approach to detect early fatty liver disease in people who are at high risk. Unlike current methods, which often rely on imaging tests or liver biopsies, the ELF test is a simple blood test that could make early detection more accessible and less invasive. This test measures specific biomarkers that indicate liver fibrosis, potentially allowing for earlier intervention and better management of the condition. By identifying fatty liver disease sooner, patients might benefit from lifestyle changes or treatments before the disease progresses.

Who Is on the Research Team?

PM

Parvez Mantry, MD

Principal Investigator

Methodist Midlothian Medical Center

Are You a Good Fit for This Trial?

Inclusion Criteria

I have been assessed for liver disease at Methodist Dallas Medical Center between November 2021 and December 2023.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Retrospective Analysis

Analysis of enhanced liver fibrosis (ELF) scores in high-risk population for NAFLD/NASH-related fibrosis

6 months

Follow-up

Participants are monitored for safety and effectiveness after analysis

4 weeks

What Are the Treatments Tested in This Trial?

Find a Clinic Near You

Who Is Running the Clinical Trial?

Methodist Health System

Lead Sponsor

Trials
156
Recruited
4,826,000+